Pfizer Stops 70% Omicron Hospitalizations in South Africa Study
- Pfizer stops 70% of omicron hospitalizations, Discovery says
- Prior infections in excess of 70% of population also cuts risk
This article is for subscribers only.
Follow our live coverage of this breaking news here.
Pfizer Inc. and BioNTech’s Covid-19 vaccine, as well as the shot developed by Johnson & Johnson, appear to largely prevent severe disease from the omicron variant, South African studies show.